Ankit Desai
Has grant
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Ankit Desai is an Associate Professor at the Indiana University School of Medicine in the United States. His research focuses on pulmonary arterial hypertension and the evaluation of right ventricular function. He has contributed to the field through recent publications exploring Mendelian randomisation analysis and clinical methods for assessing RV function.
Recent Grants
Grant: Close
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular Tachycardia
Open Date: 2017-04-01
Close Date: 2022-03-31
Grant: Close
Imaging & genomic approaches to identify cardiac fibrosis and enhance risk profiles of sickle cell-related sudden death
Open Date: 2014-01-01
Close Date: 2015-12-31
Grant: Close
Genomic Studies in a Rodent Model of Pulmonary Hypertension: A Consomics Approach
Open Date: 2007-07-01
Close Date: 2011-07-31
Articles (4)
BACKGROUND: Pulmonary hypertension (PH) represents an important phenotype in heart failure with preserved ejection fraction (HFpEF). However, management of PH-HFpEF is challenging because mechanisms involved in the regulation of PH-HFpEF remain unclear. METHODS: We used a mass spectrometry–based comparative plasma proteomics approach as a sensitive and comprehensive hypothesis-generating discovery technique to profile proteins in patients with PH-HFpEF and control subjects. We then validated and investigated the role of one of the identified proteins using in vitro cell cultures, in vivo animal models, and independent cohort of human samples. RESULTS: Plasma proteomics identified high protein abundance levels of B2M (β2-microglobulin) in patients with PH-HFpEF. Interestingly, both circulating and skeletal muscle levels of B2M were increased in mice with skeletal muscle SIRT3 (sirtuin-3) deficiency or high-fat diet–induced PH-HFpEF. Plasma and muscle biopsies from a validation cohort of PH-HFpEF patients were found to have increased B2M levels, which positively correlated with disease severity, especially pulmonary capillary wedge pressure and right atrial pressure at rest. Not only did the administration of exogenous B2M promote migration/proliferation in pulmonary arterial vascular endothelial cells but it also increased PCNA (proliferating cell nuclear antigen) expression and cell proliferation in pulmonary arterial vascular smooth muscle cells. Finally, B2m deletion improved glucose intolerance, reduced pulmonary vascular remodeling, lowered PH, and attenuated RV hypertrophy in mice with high-fat diet–induced PH-HFpEF. CONCLUSIONS: Patients with PH-HFpEF display higher circulating and skeletal muscle expression levels of B2M, the magnitude of which correlates with disease severity. Our findings also reveal a previously unknown pathogenic role of B2M in the regulation of pulmonary vascular proliferative remodeling and PH-HFpEF. These data suggest that circulating and skeletal muscle B2M can be promising targets for the management of PH-HFpEF.
Year:
2024
BACKGROUND: The ubiquitin-proteasome system regulates protein degradation and the development of pulmonary arterial hypertension (PAH), but knowledge about the role of deubiquitinating enzymes in this process is limited. UCHL1 (ubiquitin carboxyl-terminal hydrolase 1), a deubiquitinase, has been shown to reduce AKT1 (AKT serine/threonine kinase 1) degradation, resulting in higher levels. Given that AKT1 is pathological in pulmonary hypertension, we hypothesized that UCHL1 deficiency attenuates PAH development by means of reductions in AKT1. METHODS: Tissues from animal pulmonary hypertension models as well as human pulmonary artery endothelial cells from patients with PAH exhibited increased vascular UCHL1 staining and protein expression. Exposure to LDN57444, a UCHL1-specific inhibitor, reduced human pulmonary artery endothelial cell and smooth muscle cell proliferation. Across 3 preclinical PAH models, LDN57444-exposed animals, Uchl1 knockout rats ( Uchl1 −/− ), and conditional Uchl1 knockout mice ( Tie2Cre-Uchl1 fl/fl ) demonstrated reduced right ventricular hypertrophy, right ventricular systolic pressures, and obliterative vascular remodeling. Lungs and pulmonary artery endothelial cells isolated from Uchl1 −/− animals exhibited reduced total and activated Akt with increased ubiquitinated Akt levels. UCHL1-silenced human pulmonary artery endothelial cells displayed reduced lysine(K)63-linked and increased K48-linked AKT1 levels. RESULTS: Supporting experimental data, we found that rs9321, a variant in a GC-enriched region of the UCHL1 gene, is associated with reduced methylation (n=5133), increased UCHL1 gene expression in lungs (n=815), and reduced cardiac index in patients (n=796). In addition, Gadd45α (an established demethylating gene) knockout mice ( Gadd45α −/− ) exhibited reduced lung vascular UCHL1 and AKT1 expression along with attenuated hypoxic pulmonary hypertension. CONCLUSIONS: Our findings suggest that UCHL1 deficiency results in PAH attenuation by means of reduced AKT1, highlighting a novel therapeutic pathway in PAH.
Year:
2024
Year:
2020
Year:
2020
Collaborators (13)
Jason X.-J. Yuan
Professor
University of California
Daniel Flaherty
Associate Professor
Purdue University
Yen Chun Charly Lai
Assitant Professor of Medicine
Indiana University
Jeffrey R. Jacobson
University of Chicago
Joe G.N. Garcia
University of Florida
Michael Pauciulo
Assistant Professor
Cincinnati Children's Hospital Medical Center
Jason H. Karnes
-
William Nichols
Professor
Cincinnati Children's Hospital Medical Center
Noel Warfel
Associate Professor
Medical University of South Carolina
Samisubbu Naidu
Indiana University School of Medicine
Julio Duarte
Ohio State University
sebastien bonnet
Institut universitaire de cardiologie et de pneumologie de Québec
Marc Simon
Professor in Residence
UCSF Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.